Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

All 16 of Indiana’s designated senior care organizations — known as Area Agencies on Aging — are now required to have a ...

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

The third most common form of dementia is often mistaken for Alzheimer's despite different treatment needsCognitive profiles ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

China aims to have a sweeping action plan for dementia in place by 2030, encompassing all aspects of the disease, from ...